nodes	percent_of_prediction	percent_of_DWPC	metapath
Frovatriptan—migraine—Prednisone—prostate cancer	0.584	1	CpDpCtD
Frovatriptan—CYP1A2—Flutamide—prostate cancer	0.0504	0.347	CbGbCtD
Frovatriptan—CYP1A2—Estrone—prostate cancer	0.0364	0.251	CbGbCtD
Frovatriptan—CYP1A2—Conjugated Estrogens—prostate cancer	0.0238	0.164	CbGbCtD
Frovatriptan—CYP1A2—Estradiol—prostate cancer	0.0209	0.144	CbGbCtD
Frovatriptan—CYP1A2—Etoposide—prostate cancer	0.0137	0.094	CbGbCtD
Frovatriptan—Constipation—Etoposide—prostate cancer	6.9e-05	0.000327	CcSEcCtD
Frovatriptan—Conjunctivitis—Epirubicin—prostate cancer	6.89e-05	0.000327	CcSEcCtD
Frovatriptan—Dizziness—Estradiol—prostate cancer	6.88e-05	0.000326	CcSEcCtD
Frovatriptan—Dry mouth—Docetaxel—prostate cancer	6.84e-05	0.000324	CcSEcCtD
Frovatriptan—Pollakiuria—Doxorubicin—prostate cancer	6.8e-05	0.000322	CcSEcCtD
Frovatriptan—Chest pain—Capecitabine—prostate cancer	6.77e-05	0.000321	CcSEcCtD
Frovatriptan—Arthralgia—Capecitabine—prostate cancer	6.77e-05	0.000321	CcSEcCtD
Frovatriptan—Myalgia—Capecitabine—prostate cancer	6.77e-05	0.000321	CcSEcCtD
Frovatriptan—Confusional state—Docetaxel—prostate cancer	6.76e-05	0.00032	CcSEcCtD
Frovatriptan—Anxiety—Capecitabine—prostate cancer	6.75e-05	0.00032	CcSEcCtD
Frovatriptan—Anaphylactic shock—Docetaxel—prostate cancer	6.71e-05	0.000318	CcSEcCtD
Frovatriptan—Discomfort—Capecitabine—prostate cancer	6.69e-05	0.000317	CcSEcCtD
Frovatriptan—Epistaxis—Epirubicin—prostate cancer	6.69e-05	0.000317	CcSEcCtD
Frovatriptan—Sinusitis—Epirubicin—prostate cancer	6.65e-05	0.000315	CcSEcCtD
Frovatriptan—Feeling abnormal—Etoposide—prostate cancer	6.65e-05	0.000315	CcSEcCtD
Frovatriptan—Diarrhoea—Mitoxantrone—prostate cancer	6.64e-05	0.000314	CcSEcCtD
Frovatriptan—Dry mouth—Capecitabine—prostate cancer	6.62e-05	0.000314	CcSEcCtD
Frovatriptan—Vomiting—Estradiol—prostate cancer	6.62e-05	0.000314	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Etoposide—prostate cancer	6.6e-05	0.000313	CcSEcCtD
Frovatriptan—Shock—Docetaxel—prostate cancer	6.6e-05	0.000313	CcSEcCtD
Frovatriptan—Ill-defined disorder—Prednisone—prostate cancer	6.57e-05	0.000312	CcSEcCtD
Frovatriptan—Confusional state—Capecitabine—prostate cancer	6.55e-05	0.00031	CcSEcCtD
Frovatriptan—Tachycardia—Docetaxel—prostate cancer	6.54e-05	0.00031	CcSEcCtD
Frovatriptan—Headache—Estradiol—prostate cancer	6.52e-05	0.000309	CcSEcCtD
Frovatriptan—Agitation—Prednisone—prostate cancer	6.51e-05	0.000309	CcSEcCtD
Frovatriptan—Bradycardia—Epirubicin—prostate cancer	6.48e-05	0.000307	CcSEcCtD
Frovatriptan—Haemoglobin—Epirubicin—prostate cancer	6.4e-05	0.000303	CcSEcCtD
Frovatriptan—Stomatitis—Doxorubicin—prostate cancer	6.4e-05	0.000303	CcSEcCtD
Frovatriptan—Anorexia—Docetaxel—prostate cancer	6.39e-05	0.000303	CcSEcCtD
Frovatriptan—Malaise—Prednisone—prostate cancer	6.39e-05	0.000303	CcSEcCtD
Frovatriptan—Shock—Capecitabine—prostate cancer	6.39e-05	0.000303	CcSEcCtD
Frovatriptan—Rhinitis—Epirubicin—prostate cancer	6.38e-05	0.000302	CcSEcCtD
Frovatriptan—Abdominal pain—Etoposide—prostate cancer	6.38e-05	0.000302	CcSEcCtD
Frovatriptan—Body temperature increased—Etoposide—prostate cancer	6.38e-05	0.000302	CcSEcCtD
Frovatriptan—Conjunctivitis—Doxorubicin—prostate cancer	6.38e-05	0.000302	CcSEcCtD
Frovatriptan—Vertigo—Prednisone—prostate cancer	6.37e-05	0.000302	CcSEcCtD
Frovatriptan—Haemorrhage—Epirubicin—prostate cancer	6.37e-05	0.000302	CcSEcCtD
Frovatriptan—Syncope—Prednisone—prostate cancer	6.35e-05	0.000301	CcSEcCtD
Frovatriptan—Tachycardia—Capecitabine—prostate cancer	6.34e-05	0.0003	CcSEcCtD
Frovatriptan—Hypoaesthesia—Epirubicin—prostate cancer	6.33e-05	0.0003	CcSEcCtD
Frovatriptan—Pharyngitis—Epirubicin—prostate cancer	6.32e-05	0.000299	CcSEcCtD
Frovatriptan—Urinary tract disorder—Epirubicin—prostate cancer	6.29e-05	0.000298	CcSEcCtD
Frovatriptan—Hyperhidrosis—Capecitabine—prostate cancer	6.28e-05	0.000297	CcSEcCtD
Frovatriptan—Urethral disorder—Epirubicin—prostate cancer	6.24e-05	0.000296	CcSEcCtD
Frovatriptan—Loss of consciousness—Prednisone—prostate cancer	6.23e-05	0.000295	CcSEcCtD
Frovatriptan—Epistaxis—Doxorubicin—prostate cancer	6.19e-05	0.000293	CcSEcCtD
Frovatriptan—Anorexia—Capecitabine—prostate cancer	6.19e-05	0.000293	CcSEcCtD
Frovatriptan—Nausea—Estradiol—prostate cancer	6.18e-05	0.000293	CcSEcCtD
Frovatriptan—Vomiting—Mitoxantrone—prostate cancer	6.17e-05	0.000292	CcSEcCtD
Frovatriptan—Sinusitis—Doxorubicin—prostate cancer	6.16e-05	0.000292	CcSEcCtD
Frovatriptan—Convulsion—Prednisone—prostate cancer	6.14e-05	0.000291	CcSEcCtD
Frovatriptan—Visual impairment—Epirubicin—prostate cancer	6.13e-05	0.000291	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Docetaxel—prostate cancer	6.11e-05	0.000289	CcSEcCtD
Frovatriptan—Headache—Mitoxantrone—prostate cancer	6.08e-05	0.000288	CcSEcCtD
Frovatriptan—Insomnia—Docetaxel—prostate cancer	6.06e-05	0.000287	CcSEcCtD
Frovatriptan—Arthralgia—Prednisone—prostate cancer	6.03e-05	0.000286	CcSEcCtD
Frovatriptan—Myalgia—Prednisone—prostate cancer	6.03e-05	0.000286	CcSEcCtD
Frovatriptan—Paraesthesia—Docetaxel—prostate cancer	6.02e-05	0.000285	CcSEcCtD
Frovatriptan—Anxiety—Prednisone—prostate cancer	6.01e-05	0.000285	CcSEcCtD
Frovatriptan—Bradycardia—Doxorubicin—prostate cancer	6e-05	0.000284	CcSEcCtD
Frovatriptan—Dyspnoea—Docetaxel—prostate cancer	5.98e-05	0.000283	CcSEcCtD
Frovatriptan—Somnolence—Docetaxel—prostate cancer	5.96e-05	0.000282	CcSEcCtD
Frovatriptan—Discomfort—Prednisone—prostate cancer	5.96e-05	0.000282	CcSEcCtD
Frovatriptan—Hypersensitivity—Etoposide—prostate cancer	5.94e-05	0.000282	CcSEcCtD
Frovatriptan—Tinnitus—Epirubicin—prostate cancer	5.94e-05	0.000281	CcSEcCtD
Frovatriptan—Haemoglobin—Doxorubicin—prostate cancer	5.92e-05	0.000281	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Capecitabine—prostate cancer	5.91e-05	0.00028	CcSEcCtD
Frovatriptan—Flushing—Epirubicin—prostate cancer	5.91e-05	0.00028	CcSEcCtD
Frovatriptan—Rhinitis—Doxorubicin—prostate cancer	5.91e-05	0.00028	CcSEcCtD
Frovatriptan—Dyspepsia—Docetaxel—prostate cancer	5.9e-05	0.00028	CcSEcCtD
Frovatriptan—Haemorrhage—Doxorubicin—prostate cancer	5.89e-05	0.000279	CcSEcCtD
Frovatriptan—Insomnia—Capecitabine—prostate cancer	5.87e-05	0.000278	CcSEcCtD
Frovatriptan—Hypoaesthesia—Doxorubicin—prostate cancer	5.86e-05	0.000278	CcSEcCtD
Frovatriptan—Pharyngitis—Doxorubicin—prostate cancer	5.85e-05	0.000277	CcSEcCtD
Frovatriptan—Paraesthesia—Capecitabine—prostate cancer	5.83e-05	0.000276	CcSEcCtD
Frovatriptan—Decreased appetite—Docetaxel—prostate cancer	5.83e-05	0.000276	CcSEcCtD
Frovatriptan—Urinary tract disorder—Doxorubicin—prostate cancer	5.82e-05	0.000276	CcSEcCtD
Frovatriptan—Asthenia—Etoposide—prostate cancer	5.79e-05	0.000274	CcSEcCtD
Frovatriptan—Dyspnoea—Capecitabine—prostate cancer	5.79e-05	0.000274	CcSEcCtD
Frovatriptan—Anaphylactic shock—Prednisone—prostate cancer	5.78e-05	0.000274	CcSEcCtD
Frovatriptan—Fatigue—Docetaxel—prostate cancer	5.78e-05	0.000274	CcSEcCtD
Frovatriptan—Urethral disorder—Doxorubicin—prostate cancer	5.77e-05	0.000274	CcSEcCtD
Frovatriptan—Nausea—Mitoxantrone—prostate cancer	5.76e-05	0.000273	CcSEcCtD
Frovatriptan—Pain—Docetaxel—prostate cancer	5.73e-05	0.000272	CcSEcCtD
Frovatriptan—Constipation—Docetaxel—prostate cancer	5.73e-05	0.000272	CcSEcCtD
Frovatriptan—Dyspepsia—Capecitabine—prostate cancer	5.71e-05	0.000271	CcSEcCtD
Frovatriptan—Chills—Epirubicin—prostate cancer	5.71e-05	0.000271	CcSEcCtD
Frovatriptan—Pruritus—Etoposide—prostate cancer	5.71e-05	0.00027	CcSEcCtD
Frovatriptan—Shock—Prednisone—prostate cancer	5.69e-05	0.00027	CcSEcCtD
Frovatriptan—Arrhythmia—Epirubicin—prostate cancer	5.69e-05	0.000269	CcSEcCtD
Frovatriptan—Visual impairment—Doxorubicin—prostate cancer	5.68e-05	0.000269	CcSEcCtD
Frovatriptan—Tachycardia—Prednisone—prostate cancer	5.64e-05	0.000267	CcSEcCtD
Frovatriptan—Decreased appetite—Capecitabine—prostate cancer	5.64e-05	0.000267	CcSEcCtD
Frovatriptan—Fatigue—Capecitabine—prostate cancer	5.6e-05	0.000265	CcSEcCtD
Frovatriptan—Hyperhidrosis—Prednisone—prostate cancer	5.59e-05	0.000265	CcSEcCtD
Frovatriptan—Mental disorder—Epirubicin—prostate cancer	5.58e-05	0.000264	CcSEcCtD
Frovatriptan—Pain—Capecitabine—prostate cancer	5.55e-05	0.000263	CcSEcCtD
Frovatriptan—Constipation—Capecitabine—prostate cancer	5.55e-05	0.000263	CcSEcCtD
Frovatriptan—Malnutrition—Epirubicin—prostate cancer	5.54e-05	0.000263	CcSEcCtD
Frovatriptan—Feeling abnormal—Docetaxel—prostate cancer	5.53e-05	0.000262	CcSEcCtD
Frovatriptan—Diarrhoea—Etoposide—prostate cancer	5.52e-05	0.000262	CcSEcCtD
Frovatriptan—Anorexia—Prednisone—prostate cancer	5.51e-05	0.000261	CcSEcCtD
Frovatriptan—Tinnitus—Doxorubicin—prostate cancer	5.49e-05	0.00026	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Docetaxel—prostate cancer	5.48e-05	0.00026	CcSEcCtD
Frovatriptan—Flushing—Doxorubicin—prostate cancer	5.47e-05	0.000259	CcSEcCtD
Frovatriptan—Flatulence—Epirubicin—prostate cancer	5.46e-05	0.000259	CcSEcCtD
Frovatriptan—Tension—Epirubicin—prostate cancer	5.44e-05	0.000258	CcSEcCtD
Frovatriptan—Dysgeusia—Epirubicin—prostate cancer	5.43e-05	0.000257	CcSEcCtD
Frovatriptan—Nervousness—Epirubicin—prostate cancer	5.38e-05	0.000255	CcSEcCtD
Frovatriptan—Back pain—Epirubicin—prostate cancer	5.36e-05	0.000254	CcSEcCtD
Frovatriptan—Feeling abnormal—Capecitabine—prostate cancer	5.35e-05	0.000253	CcSEcCtD
Frovatriptan—Dizziness—Etoposide—prostate cancer	5.34e-05	0.000253	CcSEcCtD
Frovatriptan—Muscle spasms—Epirubicin—prostate cancer	5.33e-05	0.000252	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Capecitabine—prostate cancer	5.31e-05	0.000252	CcSEcCtD
Frovatriptan—Abdominal pain—Docetaxel—prostate cancer	5.3e-05	0.000251	CcSEcCtD
Frovatriptan—Body temperature increased—Docetaxel—prostate cancer	5.3e-05	0.000251	CcSEcCtD
Frovatriptan—Chills—Doxorubicin—prostate cancer	5.29e-05	0.00025	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Prednisone—prostate cancer	5.27e-05	0.00025	CcSEcCtD
Frovatriptan—Arrhythmia—Doxorubicin—prostate cancer	5.26e-05	0.000249	CcSEcCtD
Frovatriptan—Insomnia—Prednisone—prostate cancer	5.23e-05	0.000248	CcSEcCtD
Frovatriptan—Paraesthesia—Prednisone—prostate cancer	5.19e-05	0.000246	CcSEcCtD
Frovatriptan—Mental disorder—Doxorubicin—prostate cancer	5.16e-05	0.000245	CcSEcCtD
Frovatriptan—Ill-defined disorder—Epirubicin—prostate cancer	5.14e-05	0.000244	CcSEcCtD
Frovatriptan—Abdominal pain—Capecitabine—prostate cancer	5.13e-05	0.000243	CcSEcCtD
Frovatriptan—Body temperature increased—Capecitabine—prostate cancer	5.13e-05	0.000243	CcSEcCtD
Frovatriptan—Vomiting—Etoposide—prostate cancer	5.13e-05	0.000243	CcSEcCtD
Frovatriptan—Malnutrition—Doxorubicin—prostate cancer	5.13e-05	0.000243	CcSEcCtD
Frovatriptan—Agitation—Epirubicin—prostate cancer	5.09e-05	0.000241	CcSEcCtD
Frovatriptan—Dyspepsia—Prednisone—prostate cancer	5.09e-05	0.000241	CcSEcCtD
Frovatriptan—Headache—Etoposide—prostate cancer	5.05e-05	0.00024	CcSEcCtD
Frovatriptan—Flatulence—Doxorubicin—prostate cancer	5.05e-05	0.000239	CcSEcCtD
Frovatriptan—Tension—Doxorubicin—prostate cancer	5.03e-05	0.000238	CcSEcCtD
Frovatriptan—Decreased appetite—Prednisone—prostate cancer	5.03e-05	0.000238	CcSEcCtD
Frovatriptan—Dysgeusia—Doxorubicin—prostate cancer	5.02e-05	0.000238	CcSEcCtD
Frovatriptan—Malaise—Epirubicin—prostate cancer	5e-05	0.000237	CcSEcCtD
Frovatriptan—Fatigue—Prednisone—prostate cancer	4.99e-05	0.000236	CcSEcCtD
Frovatriptan—Nervousness—Doxorubicin—prostate cancer	4.98e-05	0.000236	CcSEcCtD
Frovatriptan—Vertigo—Epirubicin—prostate cancer	4.98e-05	0.000236	CcSEcCtD
Frovatriptan—Syncope—Epirubicin—prostate cancer	4.97e-05	0.000235	CcSEcCtD
Frovatriptan—Back pain—Doxorubicin—prostate cancer	4.96e-05	0.000235	CcSEcCtD
Frovatriptan—Constipation—Prednisone—prostate cancer	4.95e-05	0.000234	CcSEcCtD
Frovatriptan—Hypersensitivity—Docetaxel—prostate cancer	4.94e-05	0.000234	CcSEcCtD
Frovatriptan—Muscle spasms—Doxorubicin—prostate cancer	4.93e-05	0.000234	CcSEcCtD
Frovatriptan—Palpitations—Epirubicin—prostate cancer	4.9e-05	0.000232	CcSEcCtD
Frovatriptan—Loss of consciousness—Epirubicin—prostate cancer	4.87e-05	0.000231	CcSEcCtD
Frovatriptan—Asthenia—Docetaxel—prostate cancer	4.81e-05	0.000228	CcSEcCtD
Frovatriptan—Convulsion—Epirubicin—prostate cancer	4.8e-05	0.000228	CcSEcCtD
Frovatriptan—Nausea—Etoposide—prostate cancer	4.79e-05	0.000227	CcSEcCtD
Frovatriptan—Hypersensitivity—Capecitabine—prostate cancer	4.78e-05	0.000227	CcSEcCtD
Frovatriptan—Feeling abnormal—Prednisone—prostate cancer	4.77e-05	0.000226	CcSEcCtD
Frovatriptan—Ill-defined disorder—Doxorubicin—prostate cancer	4.76e-05	0.000225	CcSEcCtD
Frovatriptan—Pruritus—Docetaxel—prostate cancer	4.74e-05	0.000225	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Prednisone—prostate cancer	4.73e-05	0.000224	CcSEcCtD
Frovatriptan—Myalgia—Epirubicin—prostate cancer	4.72e-05	0.000224	CcSEcCtD
Frovatriptan—Arthralgia—Epirubicin—prostate cancer	4.72e-05	0.000224	CcSEcCtD
Frovatriptan—Chest pain—Epirubicin—prostate cancer	4.72e-05	0.000224	CcSEcCtD
Frovatriptan—Agitation—Doxorubicin—prostate cancer	4.71e-05	0.000223	CcSEcCtD
Frovatriptan—Anxiety—Epirubicin—prostate cancer	4.7e-05	0.000223	CcSEcCtD
Frovatriptan—Discomfort—Epirubicin—prostate cancer	4.66e-05	0.000221	CcSEcCtD
Frovatriptan—Asthenia—Capecitabine—prostate cancer	4.66e-05	0.000221	CcSEcCtD
Frovatriptan—Malaise—Doxorubicin—prostate cancer	4.62e-05	0.000219	CcSEcCtD
Frovatriptan—Dry mouth—Epirubicin—prostate cancer	4.61e-05	0.000219	CcSEcCtD
Frovatriptan—Vertigo—Doxorubicin—prostate cancer	4.61e-05	0.000218	CcSEcCtD
Frovatriptan—Syncope—Doxorubicin—prostate cancer	4.6e-05	0.000218	CcSEcCtD
Frovatriptan—Pruritus—Capecitabine—prostate cancer	4.59e-05	0.000218	CcSEcCtD
Frovatriptan—Diarrhoea—Docetaxel—prostate cancer	4.59e-05	0.000217	CcSEcCtD
Frovatriptan—Abdominal pain—Prednisone—prostate cancer	4.57e-05	0.000217	CcSEcCtD
Frovatriptan—Body temperature increased—Prednisone—prostate cancer	4.57e-05	0.000217	CcSEcCtD
Frovatriptan—Confusional state—Epirubicin—prostate cancer	4.56e-05	0.000216	CcSEcCtD
Frovatriptan—Palpitations—Doxorubicin—prostate cancer	4.53e-05	0.000215	CcSEcCtD
Frovatriptan—Anaphylactic shock—Epirubicin—prostate cancer	4.52e-05	0.000214	CcSEcCtD
Frovatriptan—Loss of consciousness—Doxorubicin—prostate cancer	4.51e-05	0.000214	CcSEcCtD
Frovatriptan—Shock—Epirubicin—prostate cancer	4.45e-05	0.000211	CcSEcCtD
Frovatriptan—Convulsion—Doxorubicin—prostate cancer	4.44e-05	0.000211	CcSEcCtD
Frovatriptan—Diarrhoea—Capecitabine—prostate cancer	4.44e-05	0.00021	CcSEcCtD
Frovatriptan—Dizziness—Docetaxel—prostate cancer	4.43e-05	0.00021	CcSEcCtD
Frovatriptan—Tachycardia—Epirubicin—prostate cancer	4.41e-05	0.000209	CcSEcCtD
Frovatriptan—Hyperhidrosis—Epirubicin—prostate cancer	4.37e-05	0.000207	CcSEcCtD
Frovatriptan—Myalgia—Doxorubicin—prostate cancer	4.37e-05	0.000207	CcSEcCtD
Frovatriptan—Chest pain—Doxorubicin—prostate cancer	4.37e-05	0.000207	CcSEcCtD
Frovatriptan—Arthralgia—Doxorubicin—prostate cancer	4.37e-05	0.000207	CcSEcCtD
Frovatriptan—Anxiety—Doxorubicin—prostate cancer	4.35e-05	0.000206	CcSEcCtD
Frovatriptan—Discomfort—Doxorubicin—prostate cancer	4.31e-05	0.000204	CcSEcCtD
Frovatriptan—Anorexia—Epirubicin—prostate cancer	4.31e-05	0.000204	CcSEcCtD
Frovatriptan—Dizziness—Capecitabine—prostate cancer	4.29e-05	0.000203	CcSEcCtD
Frovatriptan—Dry mouth—Doxorubicin—prostate cancer	4.27e-05	0.000202	CcSEcCtD
Frovatriptan—Vomiting—Docetaxel—prostate cancer	4.26e-05	0.000202	CcSEcCtD
Frovatriptan—Hypersensitivity—Prednisone—prostate cancer	4.26e-05	0.000202	CcSEcCtD
Frovatriptan—Confusional state—Doxorubicin—prostate cancer	4.22e-05	0.0002	CcSEcCtD
Frovatriptan—Headache—Docetaxel—prostate cancer	4.2e-05	0.000199	CcSEcCtD
Frovatriptan—Anaphylactic shock—Doxorubicin—prostate cancer	4.18e-05	0.000198	CcSEcCtD
Frovatriptan—Asthenia—Prednisone—prostate cancer	4.15e-05	0.000197	CcSEcCtD
Frovatriptan—Vomiting—Capecitabine—prostate cancer	4.13e-05	0.000196	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Epirubicin—prostate cancer	4.12e-05	0.000195	CcSEcCtD
Frovatriptan—Shock—Doxorubicin—prostate cancer	4.12e-05	0.000195	CcSEcCtD
Frovatriptan—Pruritus—Prednisone—prostate cancer	4.09e-05	0.000194	CcSEcCtD
Frovatriptan—Insomnia—Epirubicin—prostate cancer	4.09e-05	0.000194	CcSEcCtD
Frovatriptan—Tachycardia—Doxorubicin—prostate cancer	4.08e-05	0.000194	CcSEcCtD
Frovatriptan—Headache—Capecitabine—prostate cancer	4.07e-05	0.000193	CcSEcCtD
Frovatriptan—Paraesthesia—Epirubicin—prostate cancer	4.06e-05	0.000192	CcSEcCtD
Frovatriptan—Hyperhidrosis—Doxorubicin—prostate cancer	4.05e-05	0.000192	CcSEcCtD
Frovatriptan—Dyspnoea—Epirubicin—prostate cancer	4.03e-05	0.000191	CcSEcCtD
Frovatriptan—Somnolence—Epirubicin—prostate cancer	4.02e-05	0.000191	CcSEcCtD
Frovatriptan—Anorexia—Doxorubicin—prostate cancer	3.99e-05	0.000189	CcSEcCtD
Frovatriptan—Nausea—Docetaxel—prostate cancer	3.98e-05	0.000189	CcSEcCtD
Frovatriptan—Dyspepsia—Epirubicin—prostate cancer	3.98e-05	0.000189	CcSEcCtD
Frovatriptan—Diarrhoea—Prednisone—prostate cancer	3.96e-05	0.000187	CcSEcCtD
Frovatriptan—Decreased appetite—Epirubicin—prostate cancer	3.93e-05	0.000186	CcSEcCtD
Frovatriptan—Fatigue—Epirubicin—prostate cancer	3.9e-05	0.000185	CcSEcCtD
Frovatriptan—Pain—Epirubicin—prostate cancer	3.87e-05	0.000183	CcSEcCtD
Frovatriptan—Constipation—Epirubicin—prostate cancer	3.87e-05	0.000183	CcSEcCtD
Frovatriptan—Nausea—Capecitabine—prostate cancer	3.86e-05	0.000183	CcSEcCtD
Frovatriptan—Dizziness—Prednisone—prostate cancer	3.82e-05	0.000181	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Doxorubicin—prostate cancer	3.81e-05	0.000181	CcSEcCtD
Frovatriptan—Insomnia—Doxorubicin—prostate cancer	3.78e-05	0.000179	CcSEcCtD
Frovatriptan—Paraesthesia—Doxorubicin—prostate cancer	3.76e-05	0.000178	CcSEcCtD
Frovatriptan—Dyspnoea—Doxorubicin—prostate cancer	3.73e-05	0.000177	CcSEcCtD
Frovatriptan—Feeling abnormal—Epirubicin—prostate cancer	3.73e-05	0.000177	CcSEcCtD
Frovatriptan—Somnolence—Doxorubicin—prostate cancer	3.72e-05	0.000176	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Epirubicin—prostate cancer	3.7e-05	0.000175	CcSEcCtD
Frovatriptan—Dyspepsia—Doxorubicin—prostate cancer	3.68e-05	0.000175	CcSEcCtD
Frovatriptan—Vomiting—Prednisone—prostate cancer	3.68e-05	0.000174	CcSEcCtD
Frovatriptan—Decreased appetite—Doxorubicin—prostate cancer	3.64e-05	0.000172	CcSEcCtD
Frovatriptan—Headache—Prednisone—prostate cancer	3.62e-05	0.000172	CcSEcCtD
Frovatriptan—Fatigue—Doxorubicin—prostate cancer	3.61e-05	0.000171	CcSEcCtD
Frovatriptan—Pain—Doxorubicin—prostate cancer	3.58e-05	0.00017	CcSEcCtD
Frovatriptan—Constipation—Doxorubicin—prostate cancer	3.58e-05	0.00017	CcSEcCtD
Frovatriptan—Abdominal pain—Epirubicin—prostate cancer	3.58e-05	0.000169	CcSEcCtD
Frovatriptan—Body temperature increased—Epirubicin—prostate cancer	3.58e-05	0.000169	CcSEcCtD
Frovatriptan—Feeling abnormal—Doxorubicin—prostate cancer	3.45e-05	0.000163	CcSEcCtD
Frovatriptan—Nausea—Prednisone—prostate cancer	3.43e-05	0.000163	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Doxorubicin—prostate cancer	3.42e-05	0.000162	CcSEcCtD
Frovatriptan—Hypersensitivity—Epirubicin—prostate cancer	3.33e-05	0.000158	CcSEcCtD
Frovatriptan—Abdominal pain—Doxorubicin—prostate cancer	3.31e-05	0.000157	CcSEcCtD
Frovatriptan—Body temperature increased—Doxorubicin—prostate cancer	3.31e-05	0.000157	CcSEcCtD
Frovatriptan—Asthenia—Epirubicin—prostate cancer	3.24e-05	0.000154	CcSEcCtD
Frovatriptan—Pruritus—Epirubicin—prostate cancer	3.2e-05	0.000152	CcSEcCtD
Frovatriptan—Diarrhoea—Epirubicin—prostate cancer	3.09e-05	0.000147	CcSEcCtD
Frovatriptan—Hypersensitivity—Doxorubicin—prostate cancer	3.08e-05	0.000146	CcSEcCtD
Frovatriptan—Asthenia—Doxorubicin—prostate cancer	3e-05	0.000142	CcSEcCtD
Frovatriptan—Dizziness—Epirubicin—prostate cancer	2.99e-05	0.000142	CcSEcCtD
Frovatriptan—Pruritus—Doxorubicin—prostate cancer	2.96e-05	0.00014	CcSEcCtD
Frovatriptan—Vomiting—Epirubicin—prostate cancer	2.88e-05	0.000136	CcSEcCtD
Frovatriptan—Diarrhoea—Doxorubicin—prostate cancer	2.86e-05	0.000136	CcSEcCtD
Frovatriptan—Headache—Epirubicin—prostate cancer	2.83e-05	0.000134	CcSEcCtD
Frovatriptan—Dizziness—Doxorubicin—prostate cancer	2.77e-05	0.000131	CcSEcCtD
Frovatriptan—Nausea—Epirubicin—prostate cancer	2.69e-05	0.000127	CcSEcCtD
Frovatriptan—Vomiting—Doxorubicin—prostate cancer	2.66e-05	0.000126	CcSEcCtD
Frovatriptan—Headache—Doxorubicin—prostate cancer	2.62e-05	0.000124	CcSEcCtD
Frovatriptan—Nausea—Doxorubicin—prostate cancer	2.49e-05	0.000118	CcSEcCtD
Frovatriptan—CYP1A2—Metabolism—HSD3B1—prostate cancer	1.02e-05	0.00017	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—SLC22A3—prostate cancer	1.02e-05	0.00017	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—IL2—prostate cancer	1e-05	0.000167	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—TERT—prostate cancer	9.99e-06	0.000167	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—FGF10—prostate cancer	9.88e-06	0.000165	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—LPL—prostate cancer	9.88e-06	0.000165	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—ADRB2—prostate cancer	9.78e-06	0.000163	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—GSTA4—prostate cancer	9.76e-06	0.000163	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—TBXAS1—prostate cancer	9.76e-06	0.000163	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—HIF1A—prostate cancer	9.76e-06	0.000163	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—JAK2—prostate cancer	9.65e-06	0.000161	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—MAP2K1—prostate cancer	9.61e-06	0.00016	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—HIF1A—prostate cancer	9.56e-06	0.00016	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—PIK3CD—prostate cancer	9.54e-06	0.000159	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	9.54e-06	0.000159	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—VAV3—prostate cancer	9.53e-06	0.000159	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—LEP—prostate cancer	9.53e-06	0.000159	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—GSTA2—prostate cancer	9.51e-06	0.000159	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CAV1—prostate cancer	9.44e-06	0.000158	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—TGFBR2—prostate cancer	9.4e-06	0.000157	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—SULT1A1—prostate cancer	9.4e-06	0.000157	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ABCG5—prostate cancer	9.4e-06	0.000157	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—KDR—prostate cancer	9.33e-06	0.000156	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—LEP—prostate cancer	9.33e-06	0.000156	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—ITPR1—prostate cancer	9.25e-06	0.000154	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CAV1—prostate cancer	9.24e-06	0.000154	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—GSTA1—prostate cancer	9.18e-06	0.000153	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—PIK3CB—prostate cancer	9.16e-06	0.000153	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—KDR—prostate cancer	9.14e-06	0.000153	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—ESR1—prostate cancer	9.1e-06	0.000152	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—GSTO1—prostate cancer	9.07e-06	0.000151	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—HSD3B2—prostate cancer	9.07e-06	0.000151	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—NAT2—prostate cancer	9.07e-06	0.000151	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—ESR1—prostate cancer	8.91e-06	0.000149	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—BAD—prostate cancer	8.88e-06	0.000148	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—IGF1R—prostate cancer	8.84e-06	0.000148	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—CXCL8—prostate cancer	8.8e-06	0.000147	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—JAK2—prostate cancer	8.76e-06	0.000146	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	8.73e-06	0.000146	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CYP2C18—prostate cancer	8.7e-06	0.000145	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PLCB2—prostate cancer	8.7e-06	0.000145	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—LRP2—prostate cancer	8.7e-06	0.000145	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—BAD—prostate cancer	8.69e-06	0.000145	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PIK3CG—prostate cancer	8.6e-06	0.000144	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—APC—prostate cancer	8.6e-06	0.000144	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—P4HB—prostate cancer	8.53e-06	0.000142	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—EGF—prostate cancer	8.5e-06	0.000142	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—IRS1—prostate cancer	8.5e-06	0.000142	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—LPL—prostate cancer	8.48e-06	0.000142	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PIK3CG—prostate cancer	8.42e-06	0.000141	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—APC—prostate cancer	8.42e-06	0.000141	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—IL2—prostate cancer	8.41e-06	0.00014	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PDGFRB—prostate cancer	8.4e-06	0.00014	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—EGF—prostate cancer	8.32e-06	0.000139	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—IRS1—prostate cancer	8.32e-06	0.000139	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—PIK3CB—prostate cancer	8.32e-06	0.000139	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—SLC22A1—prostate cancer	8.3e-06	0.000139	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—GSK3B—prostate cancer	8.25e-06	0.000138	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	8.2e-06	0.000137	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—ITGB3—prostate cancer	8.19e-06	0.000137	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—INS—prostate cancer	8.14e-06	0.000136	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—SULT2A1—prostate cancer	8.09e-06	0.000135	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—GSK3B—prostate cancer	8.08e-06	0.000135	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—CXCL8—prostate cancer	7.99e-06	0.000133	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CREBBP—prostate cancer	7.97e-06	0.000133	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—INS—prostate cancer	7.97e-06	0.000133	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—MED12—prostate cancer	7.96e-06	0.000133	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—ERBB3—prostate cancer	7.94e-06	0.000133	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—FGFR2—prostate cancer	7.93e-06	0.000132	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—GNG5—prostate cancer	7.89e-06	0.000132	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—IGF1—prostate cancer	7.87e-06	0.000131	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—EGFR—prostate cancer	7.83e-06	0.000131	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CREBBP—prostate cancer	7.81e-06	0.00013	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—IGF1—prostate cancer	7.71e-06	0.000129	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—EGFR—prostate cancer	7.67e-06	0.000128	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—IL2—prostate cancer	7.64e-06	0.000128	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—TERT—prostate cancer	7.61e-06	0.000127	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—MAP2K1—prostate cancer	7.61e-06	0.000127	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—NCOA3—prostate cancer	7.6e-06	0.000127	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PIK3CD—prostate cancer	7.56e-06	0.000126	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—PIK3CA—prostate cancer	7.49e-06	0.000125	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—SERPINE1—prostate cancer	7.48e-06	0.000125	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	7.47e-06	0.000125	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—MAP2K1—prostate cancer	7.45e-06	0.000124	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PIK3CD—prostate cancer	7.4e-06	0.000124	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—KRAS—prostate cancer	7.4e-06	0.000124	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—PIK3CA—prostate cancer	7.33e-06	0.000122	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—SERPINE1—prostate cancer	7.32e-06	0.000122	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—HIF1A—prostate cancer	7.28e-06	0.000122	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—HPGDS—prostate cancer	7.25e-06	0.000121	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—KRAS—prostate cancer	7.25e-06	0.000121	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—FGF2—prostate cancer	7.24e-06	0.000121	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CYP2C19—prostate cancer	7.21e-06	0.00012	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—NOS3—prostate cancer	7.14e-06	0.000119	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—LEP—prostate cancer	7.11e-06	0.000119	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—FGF2—prostate cancer	7.09e-06	0.000118	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CAV1—prostate cancer	7.04e-06	0.000118	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ACHE—prostate cancer	7.04e-06	0.000117	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—GSTT1—prostate cancer	7.04e-06	0.000117	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—NOS3—prostate cancer	6.99e-06	0.000117	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—KDR—prostate cancer	6.96e-06	0.000116	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CYP2A6—prostate cancer	6.95e-06	0.000116	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—JAK2—prostate cancer	6.94e-06	0.000116	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	6.93e-06	0.000116	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—PIK3CA—prostate cancer	6.8e-06	0.000113	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—JAK2—prostate cancer	6.79e-06	0.000113	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—ESR1—prostate cancer	6.78e-06	0.000113	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—MDM2—prostate cancer	6.77e-06	0.000113	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—AKR1C3—prostate cancer	6.77e-06	0.000113	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PRKACB—prostate cancer	6.73e-06	0.000112	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—ERBB2—prostate cancer	6.68e-06	0.000111	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CYP17A1—prostate cancer	6.66e-06	0.000111	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—PIK3CA—prostate cancer	6.66e-06	0.000111	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—MDM2—prostate cancer	6.63e-06	0.000111	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—BAD—prostate cancer	6.62e-06	0.000111	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PIK3CB—prostate cancer	6.59e-06	0.00011	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	6.57e-06	0.00011	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—ERBB2—prostate cancer	6.54e-06	0.000109	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PIK3CB—prostate cancer	6.45e-06	0.000108	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PIK3CG—prostate cancer	6.41e-06	0.000107	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—APC—prostate cancer	6.41e-06	0.000107	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—NCOA2—prostate cancer	6.35e-06	0.000106	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—IRS1—prostate cancer	6.34e-06	0.000106	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—EGF—prostate cancer	6.34e-06	0.000106	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CXCL8—prostate cancer	6.33e-06	0.000106	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CXCL8—prostate cancer	6.2e-06	0.000103	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CDKN1B—prostate cancer	6.18e-06	0.000103	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—GSK3B—prostate cancer	6.15e-06	0.000103	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—AKT1—prostate cancer	6.12e-06	0.000102	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—INS—prostate cancer	6.07e-06	0.000101	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CASP3—prostate cancer	6.06e-06	0.000101	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—SLC5A5—prostate cancer	6.05e-06	0.000101	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CDKN1B—prostate cancer	6.05e-06	0.000101	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—IL2—prostate cancer	6.05e-06	0.000101	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—IL6—prostate cancer	6.02e-06	0.0001	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—AKT1—prostate cancer	5.99e-06	0.0001	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CREBBP—prostate cancer	5.95e-06	9.93e-05	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CASP3—prostate cancer	5.93e-06	9.9e-05	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—IL2—prostate cancer	5.92e-06	9.89e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CYP2E1—prostate cancer	5.91e-06	9.87e-05	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CCND1—prostate cancer	5.9e-06	9.85e-05	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—IL6—prostate cancer	5.89e-06	9.84e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—IGF1—prostate cancer	5.87e-06	9.8e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—NQO1—prostate cancer	5.85e-06	9.76e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—EGFR—prostate cancer	5.84e-06	9.75e-05	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CTNNB1—prostate cancer	5.84e-06	9.75e-05	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CCND1—prostate cancer	5.78e-06	9.64e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—TH—prostate cancer	5.76e-06	9.62e-05	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—MMP9—prostate cancer	5.73e-06	9.56e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	5.73e-06	9.56e-05	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CTNNB1—prostate cancer	5.72e-06	9.55e-05	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CDKN1A—prostate cancer	5.71e-06	9.52e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CYP3A4—prostate cancer	5.7e-06	9.52e-05	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PTEN—prostate cancer	5.69e-06	9.5e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—MAP2K1—prostate cancer	5.68e-06	9.47e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	5.67e-06	9.47e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PIK3CD—prostate cancer	5.64e-06	9.41e-05	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—MMP9—prostate cancer	5.61e-06	9.36e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CYP1B1—prostate cancer	5.61e-06	9.36e-05	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CDKN1A—prostate cancer	5.59e-06	9.33e-05	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—PIK3CA—prostate cancer	5.58e-06	9.32e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—SERPINE1—prostate cancer	5.58e-06	9.31e-05	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PTEN—prostate cancer	5.57e-06	9.3e-05	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—AKT1—prostate cancer	5.55e-06	9.27e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—KRAS—prostate cancer	5.52e-06	9.21e-05	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—AKT1—prostate cancer	5.44e-06	9.08e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—GGT1—prostate cancer	5.43e-06	9.06e-05	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—EP300—prostate cancer	5.43e-06	9.06e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—FGF2—prostate cancer	5.4e-06	9.01e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—NCOA1—prostate cancer	5.35e-06	8.93e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—NOS3—prostate cancer	5.32e-06	8.89e-05	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—EP300—prostate cancer	5.32e-06	8.87e-05	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—SRC—prostate cancer	5.28e-06	8.81e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CYP19A1—prostate cancer	5.27e-06	8.8e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—JAK2—prostate cancer	5.17e-06	8.64e-05	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—SRC—prostate cancer	5.17e-06	8.63e-05	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—VEGFA—prostate cancer	5.14e-06	8.58e-05	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—STAT3—prostate cancer	5.09e-06	8.5e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—RXRA—prostate cancer	5.09e-06	8.49e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—PIK3CA—prostate cancer	5.07e-06	8.46e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—MDM2—prostate cancer	5.05e-06	8.43e-05	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—VEGFA—prostate cancer	5.03e-06	8.4e-05	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—STAT3—prostate cancer	4.99e-06	8.32e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—ERBB2—prostate cancer	4.98e-06	8.31e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	4.95e-06	8.26e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PIK3CB—prostate cancer	4.91e-06	8.2e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—COMT—prostate cancer	4.9e-06	8.18e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—GSTP1—prostate cancer	4.88e-06	8.14e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ITPR1—prostate cancer	4.8e-06	8.01e-05	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—MYC—prostate cancer	4.73e-06	7.9e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CXCL8—prostate cancer	4.72e-06	7.88e-05	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—TGFB1—prostate cancer	4.72e-06	7.88e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	4.72e-06	7.88e-05	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—MYC—prostate cancer	4.63e-06	7.73e-05	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—EGFR—prostate cancer	4.63e-06	7.72e-05	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—TGFB1—prostate cancer	4.62e-06	7.71e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CDKN1B—prostate cancer	4.61e-06	7.7e-05	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—AKT1—prostate cancer	4.56e-06	7.61e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—TYMS—prostate cancer	4.53e-06	7.57e-05	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—EGFR—prostate cancer	4.53e-06	7.56e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CASP3—prostate cancer	4.52e-06	7.54e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—IL2—prostate cancer	4.51e-06	7.53e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—IL6—prostate cancer	4.49e-06	7.5e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—GSTM1—prostate cancer	4.48e-06	7.48e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CCND1—prostate cancer	4.4e-06	7.34e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—LPL—prostate cancer	4.4e-06	7.34e-05	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—KRAS—prostate cancer	4.37e-06	7.3e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CTNNB1—prostate cancer	4.36e-06	7.27e-05	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—KRAS—prostate cancer	4.28e-06	7.14e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—MMP9—prostate cancer	4.27e-06	7.13e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CDKN1A—prostate cancer	4.26e-06	7.1e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CYP1A1—prostate cancer	4.25e-06	7.09e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PTEN—prostate cancer	4.25e-06	7.09e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ERCC2—prostate cancer	4.21e-06	7.03e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—AKT1—prostate cancer	4.14e-06	6.91e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—EP300—prostate cancer	4.05e-06	6.76e-05	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PIK3CA—prostate cancer	4.02e-06	6.7e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—MTHFR—prostate cancer	3.96e-06	6.61e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—SRC—prostate cancer	3.94e-06	6.57e-05	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PIK3CA—prostate cancer	3.93e-06	6.56e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PPARA—prostate cancer	3.89e-06	6.49e-05	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—TP53—prostate cancer	3.89e-06	6.49e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—VEGFA—prostate cancer	3.84e-06	6.4e-05	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—TP53—prostate cancer	3.8e-06	6.35e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—STAT3—prostate cancer	3.8e-06	6.34e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CAV1—prostate cancer	3.65e-06	6.1e-05	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—IL6—prostate cancer	3.56e-06	5.94e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—MYC—prostate cancer	3.53e-06	5.89e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—TGFB1—prostate cancer	3.52e-06	5.88e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.49e-06	5.83e-05	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—IL6—prostate cancer	3.48e-06	5.81e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—EGFR—prostate cancer	3.45e-06	5.76e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PIK3CG—prostate cancer	3.33e-06	5.55e-05	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—AKT1—prostate cancer	3.28e-06	5.48e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—KRAS—prostate cancer	3.26e-06	5.44e-05	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—AKT1—prostate cancer	3.21e-06	5.36e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—INS—prostate cancer	3.15e-06	5.26e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CREBBP—prostate cancer	3.09e-06	5.15e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PIK3CA—prostate cancer	3e-06	5e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PIK3CD—prostate cancer	2.93e-06	4.88e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—TP53—prostate cancer	2.9e-06	4.84e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—NOS3—prostate cancer	2.76e-06	4.61e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—IL6—prostate cancer	2.65e-06	4.43e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PIK3CB—prostate cancer	2.55e-06	4.26e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PTGS2—prostate cancer	2.53e-06	4.22e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—AKT1—prostate cancer	2.45e-06	4.08e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PTEN—prostate cancer	2.2e-06	3.68e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—EP300—prostate cancer	2.1e-06	3.51e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PIK3CA—prostate cancer	1.55e-06	2.59e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—AKT1—prostate cancer	1.27e-06	2.12e-05	CbGpPWpGaD
